thalidomide has been researched along with Anemia, Sickle Cell in 12 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide alone was also more effective in decreasing H3K27 methylation." | 2.78 | Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate. ( Abroun, S; Ahmadvand, M; Chegeni, R; Fard, AD; Hajifathali, A; Kaviani, S; Mohammadi, MM; Noruzinia, M; Saki, N; Soleimani, M; Zonoubi, Z, 2013) |
| "Current therapeutic strategies for sickle cell anemia are aimed at reactivating fetal hemoglobin." | 1.43 | Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. ( Al-Abed, Y; Allen, SL; An, X; Appiah-Kubi, AO; Blanc, L; Chan, KW; Didier, S; Dulmovits, BM; Gallagher, PG; Gould, M; Hale, J; He, M; Husain-Krautter, S; Lipton, JM; Liu, JM; Marambaud, P; Mohandas, N; Papoin, J; Singh, SA; Taylor, N; Vlachos, A, 2016) |
| "Pomalidomide is a potent structural analog of thalidomide and member of a new class of immunomodulatory drugs." | 1.37 | Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. ( Corral, LG; Kutlar, A; Kutlar, F; Meiler, SE; Moutouh-de Parseval, LA; Swerdlow, PS; Wade, M; Xue, Y; Yerigenahally, SD, 2011) |
| "Sickle-cell disease (SCD) and beta thalassemia constitute worldwide public health problems." | 1.35 | Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. ( Brady, H; Chan, K; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Morris, CL; Moutouh-de Parseval, LA; Muller, G; Verhelle, D, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Melo, TRF | 1 |
| Kumkhaek, C | 1 |
| Fernandes, GFDS | 2 |
| Lopes Pires, ME | 1 |
| Chelucci, RC | 1 |
| Barbieri, KP | 1 |
| Coelho, F | 1 |
| Capote, TSO | 1 |
| Lanaro, C | 4 |
| Carlos, IZ | 1 |
| Marcondes, S | 1 |
| Chegaev, K | 1 |
| Guglielmo, S | 1 |
| Fruttero, R | 1 |
| Chung, MC | 2 |
| Costa, FF | 4 |
| Rodgers, GP | 1 |
| Dos Santos, JL | 4 |
| Khandros, E | 1 |
| Huang, P | 1 |
| Peslak, SA | 1 |
| Sharma, M | 1 |
| Abdulmalik, O | 1 |
| Giardine, BM | 1 |
| Zhang, Z | 1 |
| Keller, CA | 1 |
| Hardison, RC | 1 |
| Blobel, GA | 1 |
| de Melo, TRF | 1 |
| Dulmovits, BM | 2 |
| de Souza, CM | 1 |
| He, M | 2 |
| Al Abed, Y | 1 |
| Blanc, L | 2 |
| Franco-Penteado, CF | 2 |
| Silva, FH | 1 |
| Fertrin, KY | 1 |
| Wade, M | 3 |
| Yerigenahally, S | 2 |
| de Melo, TR | 1 |
| Chin, CM | 1 |
| Kutlar, A | 3 |
| Meiler, SE | 3 |
| Fard, AD | 2 |
| Kaviani, S | 2 |
| Noruzinia, M | 2 |
| Soleimani, M | 1 |
| Abroun, S | 1 |
| Chegeni, R | 1 |
| Hajifathali, A | 1 |
| Zonoubi, Z | 1 |
| Ahmadvand, M | 1 |
| Mohammadi, MM | 1 |
| Saki, N | 2 |
| Mortaz, E | 1 |
| Appiah-Kubi, AO | 1 |
| Papoin, J | 1 |
| Hale, J | 1 |
| Al-Abed, Y | 1 |
| Didier, S | 1 |
| Gould, M | 1 |
| Husain-Krautter, S | 1 |
| Singh, SA | 1 |
| Chan, KW | 1 |
| Vlachos, A | 1 |
| Allen, SL | 1 |
| Taylor, N | 1 |
| Marambaud, P | 1 |
| An, X | 1 |
| Gallagher, PG | 1 |
| Mohandas, N | 1 |
| Lipton, JM | 1 |
| Liu, JM | 1 |
| Kutlar, F | 1 |
| Yerigenahally, SD | 1 |
| Xue, Y | 1 |
| Moutouh-de Parseval, LA | 2 |
| Corral, LG | 3 |
| Swerdlow, PS | 1 |
| Lima, LM | 1 |
| Gambero, S | 1 |
| Alexandre-Moreira, MS | 1 |
| Chung, M | 1 |
| Ferguson, GD | 2 |
| Jensen-Pergakes, K | 2 |
| Wilkey, C | 1 |
| Jhaveri, U | 1 |
| Richard, N | 1 |
| Verhelle, D | 2 |
| De Parseval, LM | 1 |
| Xie, W | 1 |
| Morris, CL | 2 |
| Brady, H | 2 |
| Chan, K | 2 |
| Glezer, E | 1 |
| Muller, G | 1 |
| Achs, R | 1 |
| Harper, RG | 1 |
2 reviews available for thalidomide and Anemia, Sickle Cell
| Article | Year |
|---|---|
Induction of fetal hemoglobin as a novel therapeutic strategy for β-hemoglobinopathy.
Topics: Anemia, Sickle Cell; Angiogenesis Inhibitors; Animals; beta-Thalassemia; Butyric Acid; Drug Synergis | 2014 |
Dermatoglyphics.
Topics: Abnormalities, Drug-Induced; Anemia, Sickle Cell; Anencephaly; Cerebral Palsy; Chromosome Aberration | 1968 |
1 trial available for thalidomide and Anemia, Sickle Cell
| Article | Year |
|---|---|
Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate.
Topics: AC133 Antigen; Anemia, Sickle Cell; Antigens, CD; beta-Thalassemia; Butyrates; Cells, Cultured; Eryt | 2013 |
9 other studies available for thalidomide and Anemia, Sickle Cell
| Article | Year |
|---|---|
Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation.
Topics: Acetic Acid; Acetylation; Anemia, Sickle Cell; Dose-Response Relationship, Drug; Drug Discovery; gam | 2018 |
Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts.
Topics: Adult; Anemia, Sickle Cell; Cell Line; Cell Separation; Cells, Cultured; Erythroblasts; Erythroid Ce | 2020 |
Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment.
Topics: Anemia, Sickle Cell; Dose-Response Relationship, Drug; Humans; Molecular Structure; Structure-Activi | 2021 |
A thalidomide-hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes.
Topics: Anemia, Sickle Cell; Animals; Cytokines; Disease Models, Animal; Fetal Hemoglobin; Hydroxyurea; Infl | 2018 |
Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors.
Topics: Adult; Anemia, Sickle Cell; beta-Globins; Carrier Proteins; Erythroid Precursor Cells; Erythropoiesi | 2016 |
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bone Marrow; Disease Models, Animal; Erythropoies | 2011 |
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms.
Topics: Acetic Acid; Analgesics; Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Antisickling Agents | 2011 |
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2.
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cyclooxygenase 2; C | 2007 |
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Topics: Anemia, Sickle Cell; Antigens, CD34; Antineoplastic Agents; Antisickling Agents; beta-Thalassemia; B | 2008 |